BRCA2 and neoplasm: We further analyzed the 35 high grade serous/undifferentiated tumour samples that did not contain BRCA2 mutations using a combination of MIP copy number, qRT-PCR, and immunohistochemistry in order to determine whether these different groups could be classified according to specific molecular features other than BRCA1 or BRCA2 abnormalities (Figure 3).